Emmetrope Ophthalmics LLC, (aka “Emmecell”) is a privately held, clinical-stage biotechnology company pioneering the discovery and development of cell-based therapies for the treatment of eye diseases via its exclusive Magnetic Cell Delivery (MCD) nanoparticle platform technology.
Through its MCD platform, Emmecell solves the challenges of delivery, retention, and integration of cell therapies by leveraging magnetic nanoparticles to effectively localize and integrate cell therapies to the appropriate target tissue.
Emmecell has a broad IP portfolio and is focusing its initial efforts on ophthalmic indications. The Company’s lead product is EO2002 for treatment for corneal edema, the most common indication for corneal transplantation.
Headquartered in Menlo Park, CA, Emmecell is also the parent company of CellMP (Cell Manufacturing and Production LLC, www.cellmp.com), which provides current good manufacturing practices (cGMP) manufacturing services.